Lisa Calhoun tried… massage, acupunture, yoga, physical therapy, over the counter medications BUT everything she tried either......did nothing OR made the pain worse...
Until she discovered the 12-second “Neural Pain Switch” that finally erase the nonstop, throbbing joint pain stealing her independence, freedom, and confidence – FOR GOOD!
HHS recently released the Office of the National Coordinator for Health IT (ONC’s) Cures Act Final Rule that will help give patients safe, secure access to their health data, spur innovation, and address industry-wide information blocking practices.
The final rule implements interoperability provisions of the bipartisan 21st Century Cures Act and promotes patient access to their health record. Putting patients in charge of their health records is a key piece of patient control in health care, and patient control is at the center of our work toward a value-based health care system.
Watch this recorded webinar on the final rule. We also have a website dedicated to the final rule with overview information and detailed fact sheets. This website will continue to be updated on a regular basis with additional resources. www.healthit.gov/curesrule
MCG’s Managing Editor of Ambulatory Care, Stacey Popko, MD, MBA, discusses the 21st Century Cures Act and what impact it may have on drug development. Learn more about our ambulatory guidance content here: https://www.mcg.com/care-guidelines/ambulatory-care/.
The passage of the 21st Century Cures Act has drawn both applause and criticism. A sweeping bipartisan effort with multiple components, the law dramatically boosts funding for medical research, particularly in areas such as cancer and brain disease. The law also relaxes regulatory processes for pharmaceuticals and medical devices. In doing so, the law’s supporters point to the potential for faster treatments benefiting from a streamlined approval process. Critics raise concerns that safety and efficacy might be compromised, with potentially devastating consequences. And the law also has been questioned for failing to explicitly address high drug prices, a growing public issue. These debates are unfolding as the Trump administration is expected to imminently announce its choice for a new FDA commissioner, who will head an agency directly impacted by the Cures act. In this Forum, experts will explore the implications of the law for biomedicine, regulation, pharmaceuticals and patient advocacy.
This Forum event was presented jointly with STAT on February 27, 2017.
Watch the entire series at ForumHSPH.org. Video Rating: / 5
